As Ang-2 mediates resistance to anti-VEGF therapy as well, and Ang-2 targeting may promote restoration of the hepatic vasculature, the addition of an Ang-2-targeting compound to the combination of anti-VEGF and ICI therapy could potentially further improve its efficacy in HCC patients [26]. The gene discussed is ANGPT2; the disease is hepatocellular carcinoma.